Skip to content
Subscriber Only

Mylan Misled Investors Over EpiPen Pricing Probe, SEC Says

  • Drugmaker, SEC make official $30 million settlement deal
  • Company didn’t tell investors about probe or risks, SEC says
Updated on

Mylan NV misled investors for at least a year about a Justice Department investigation into the allergy shot EpiPen that would eventually cost the company nearly $500 million, the U.S. Securities and Exchange Commission said Friday.

The settlement appears to close one part of a long-running saga over a product that boosted Mylan’s sales but also brought controversy. Under the agreement with the SEC, first disclosed as a settlement in principle by Mylan in July, the drugmaker will pay $30 million.